Patients with chronic kidney disease (CKD) have an enhanced risk of cardiovascular (CV)
morbidity and mortality when compared with age-and gender-matched individuals with …

Trimethylamine N-oxide (TMAO) is a circulating metabolite that has been implicated in the
development of atherosclerosis and cardiovascular disease (CVD). In this paper, we identify …

ABSTRACT Background Trimethylamine-N-oxide (TMAO) is a gut microbiota–derived
metabolite produced from dietary nutrients. Many studies have discovered that circulating …

The host-microbiota co-metabolite trimethylamine N-oxide (TMAO) is linked to increased
cardiovascular risk but how its circulating levels are regulated remains unclear. We applied …

Background and Purpose Chronic kidney disease (CKD) is a global public health problem
and one of the leading causes of all‐cause mortality. However, the pathogenic mechanisms …

Background Trimethylamine N‐oxide (TMAO) is a gut microbiota‐dependent metabolite of
dietary choline, L‐carnitine, and phosphatidylcholine‐rich foods. On the basis of …

Patients with chronic kidney disease (CKD) have elevated circulating levels of
trimethylamine N-oxide (TMAO), a metabolite derived from gut microbes and associated with …

Aims Little is known about associations of trimethylamine N-oxide (TMAO), a novel gut
microbiota-generated metabolite of dietary phosphatidylcholine and carnitine, and its …

Objective Gut microbiota‐produced trimethylamine N‐oxide (TMAO) is a risk factor for
cardiovascular events. However, conflicting findings regarding the link between plasma …

Elevated circulating trimethylamine N-oxide (TMAO) concentrations have been observed in
patients with chronic kidney disease (CKD). We aimed to systematically estimate and …